Form 4: Ligand Pharmaceuticals Director Stephen Sabba Reports Stock Transactions
SEC Form 4 Filing
Director Stephen Sabba reports acquisition and disposal of Ligand Pharmaceuticals stock and derivative securities.
Summary
- Stephen Sabba, a director of Ligand Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
- On March 5, 2024, Sabba acquired 2,893 shares of common stock at $0.00 and disposed of 1,893 shares at $74.3.
- Following these transactions, Sabba beneficially owns 28,926 shares of Ligand Pharmaceuticals.
- Sabba also exercised non-qualified stock options for 2,893 shares at a price of $67.53.
- The reported transactions include adjustments related to the OmniAb Inc. separation from Ligand.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard disclosure of stock transactions by a company director.
Industry Context
Form 4 filings are standard disclosures required by the SEC for company insiders, providing transparency into their trading activities and potential alignment with company performance.
Stakeholder Impact
- The transactions may be of interest to shareholders as they provide insight into the director's view of the company's stock value.
Key Dates
| Date | Description |
|---|---|
| 06/06/2014 | Previously reported grant of 3,312 shares |
| 05/10/2023 | Incorrectly filed Form 4 for disposed shares |
| 03/05/2024 | Date of stock acquisition and disposal, and option exercise |
| 03/07/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.